product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
p42 MAP Kinase (Erk2) Antibody
catalog :
9108
clonality :
polyclonal
host :
rabbit
conjugate :
nonconjugated
reactivity :
human, mouse, rat
application :
western blot, western blot knockout validation, immunohistochemistry knockout validation
citations: 15
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry knockout validation; mouse; fig 3
  • western blot knockout validation; mouse; fig 3
Kurioka T, Matsunobu T, Satoh Y, Niwa K, Endo S, Fujioka M, et al. ERK2 mediates inner hair cell survival and decreases susceptibility to noise-induced hearing loss. Sci Rep. 2015;5:16839 pubmed publisher
  • western blot; human; loading ...; fig 6b
Fischer A, Harrison K, Ramirez Y, Auer D, Chowdhury S, Prusty B, et al. Chlamydia trachomatis-containing vacuole serves as deubiquitination platform to stabilize Mcl-1 and to interfere with host defense. elife. 2017;6: pubmed publisher
  • western blot; human; 1:1000; loading ...; fig 6d
Wang S, Cheng Y, Zheng Y, He Z, Chen W, Zhou W, et al. PRKAR1A is a functional tumor suppressor inhibiting ERK/Snail/E-cadherin pathway in lung adenocarcinoma. Sci Rep. 2016;6:39630 pubmed publisher
  • western blot; mouse; loading ...; fig 4b
  • western blot; human; loading ...; fig 1b
Macritchie N, Volpert G, Al Washih M, Watson D, Futerman A, Kennedy S, et al. Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension. Cell Signal. 2016;28:946-55 pubmed publisher
  • western blot; rat; loading ...; fig 7
Guo H, Liu B, Hou L, The E, Li G, Wang D, et al. The role of mAKAPβ in the process of cardiomyocyte hypertrophy induced by angiotensin II. Int J Mol Med. 2015;35:1159-68 pubmed publisher
  • western blot; human
Wnorowski A, Sadowska M, Paul R, Singh N, Boguszewska Czubara A, Jimenez L, et al. Activation of β2-adrenergic receptor by (R,R')-4'-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells. Cell Signal. 2015;27:997-1007 pubmed publisher
Palam L, Mali R, Ramdas B, Srivatsan S, Visconte V, Tiu R, et al. Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway. JCI Insight. 2018;3: pubmed publisher
Kolev M, Kemper C. Keeping It All Going-Complement Meets Metabolism. Front Immunol. 2017;8:1 pubmed publisher
He X, Liu Z, Xia Y, Xu J, Lv G, Wang L, et al. HOXB7 overexpression promotes cell proliferation and correlates with poor prognosis in gastric cancer patients by inducing expression of both AKT and MARKs. Oncotarget. 2017;8:1247-1261 pubmed publisher
Cui T, Srivastava A, Han C, Yang L, Zhao R, Zou N, et al. XPC inhibits NSCLC cell proliferation and migration by enhancing E-Cadherin expression. Oncotarget. 2015;6:10060-72 pubmed
Akkerman S, Prickaerts J, Bruder A, Wolfs K, De Vry J, Vanmierlo T, et al. PDE5 inhibition improves object memory in standard housed rats but not in rats housed in an enriched environment: implications for memory models?. PLoS ONE. 2014;9:e111692 pubmed publisher
Yan B, Kuick C, Lim M, Venkataraman K, Tennakoon C, Loh E, et al. Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas. PLoS ONE. 2014;9:e106575 pubmed publisher
Sosanya N, Huang P, Cacheaux L, Chen C, Nguyen K, Perrone Bizzozero N, et al. Degradation of high affinity HuD targets releases Kv1.1 mRNA from miR-129 repression by mTORC1. J Cell Biol. 2013;202:53-69 pubmed publisher
Dufresne A, Bertucci F, Penel N, Le Cesne A, Bui B, Tubiana Hulin M, et al. Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. Br J Cancer. 2010;103:482-5 pubmed publisher
Gupta P, Ho P, Ha S, Lin Y, Wei L. HDAC3 as a molecular chaperone for shuttling phosphorylated TR2 to PML: a novel deacetylase activity-independent function of HDAC3. PLoS ONE. 2009;4:e4363 pubmed publisher
product information
SKU :
9108S
Product-Name :
p42 MAP Kinase (Erk2) Antibody
Size :
100 ul
Price-(USD) :
235 USD
Species-x-Reactivity :
H, M, R, Mk
Applications :
Western blot
Product-Category :
MAP Kinase Signaling
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Polyclonal Antibody
MW :
42
Host :
Rabbit
Target :
ERK2
Primary-Protein :
ERK2
Alt-Names :
ERK,ERK-2,ERK2,ERT1,Extracellular signal-regulated kinase 2,MAP kinase 1,MAP kinase 2,MAP kinase isoform p42,MAPK 1,MAPK 2,MAPK1,MAPK2,MK01,Mitogen-activated protein kinase 1,Mitogen-activated protein kinase 2,P42MAPK,PRKM1,PRKM2,extracellular signal-regulated kinase-2,p40,p41,p41mapk,p42-MAPK,protein tyrosine kinase ERK2
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.